Currently, we only provide ketamine-assisted therapy in the treatment of depression, anxiety, ptsd, ocd, and bipolar disorder. Our clinical team has been closely following the clinical trials and policy-level developments regarding other psychedelic therapeutics such as psilocybin and mdma. We hope to be able to provide additional modalities of psychedelic therapy with the passage of local and federal laws that would decriminalize such substances and allow for “off-label” medical applications.
Comments
0 comments
Article is closed for comments.